Qlife announced that its core patent for the Egoo system has been granted in the EU and other countries in the European market, as well as in the United Kingdom. The key feature of the innovation is the ability to perform analysis in a microenvironment with fixed alignment, so no variability is seen between analysis and readout. The new patent is already carried on to international markets beyond Europe and provides Qlife with a robust intellectual property position as the company moves towards commercialization.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0012 SEK | +9.09% | -29.41% | -93.97% |
07-02 | Qlife Participates Research Trial for People Living with PKU and Gets Positive Data | CI |
06-03 | Qlife Starts Clinical Trial in China with First Biomarker on Egoo Health | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-93.97% | 379K | |
-6.24% | 180B | |
-6.08% | 98.89B | |
-5.98% | 66.26B | |
-9.35% | 44.61B | |
+8.34% | 44.02B | |
+10.13% | 40.12B | |
+11.88% | 29.19B | |
-8.38% | 23.64B | |
+13.33% | 23.41B |
- Stock Market
- Equities
- QLIFE Stock
- News Qlife Holding AB
- Qlife Announces its Core Patent for Egoo System Grants in EU and Other Countries in European Market, as Well as in United Kingdom